CDER Director Sees Behind-The-Counter Switches As Best Bet
This article was originally published in The Tan Sheet
Executive Summary
FDA drug center chief Janet Woodcock says behind-the-counter switches would be the most effective method to make Rx drugs available without prescriptions, particularly to help treat chronic conditions.
You may also be interested in...
OTC Switch “Blueprint” Could Help Regulatory Navigation – Researchers
Rx-to-OTC switch questions that FDA asked advisory committees over the past 10 years can help guide future sponsors to success, says the lead researcher in an analysis of the agency’s switch actions.
Asthma Treatment OTC Switches Would Face Tough Barriers
Prescription asthma drugs on the brink of patent expiry could breathe new life into Rx-to-OTC switches, but not without fierce opposition from some health care providers.
FDA Expects OTC Switch Self-Selection Studies To Probe Consumer Thinking
A draft guidance on designing self-selection studies in support of Rx-to-OTC switches reflects FDA’s interest in drilling down for greater insight into consumers’ thought processes.